Zofran (Ondansetron hydrochloride) injection

Area of Science:

• Anesthesiology
• Pharmacology
• Surgical Care

Background:

• Postoperative nausea and vomiting (PONV) affect approximately 30% of patients undergoing surgical procedures.
• Existing treatments for PONV have varying efficacy and side effect profiles.
• Zofran (ondansetron) has a history of use in managing chemotherapy-induced nausea and vomiting since 1991.

Purpose of the Study:

• To evaluate the efficacy and safety of Zofran injection for the prevention of postoperative nausea and vomiting.
• To determine the optimal dosage and administration route for Zofran in the perioperative setting.

Main Methods:

• The Food and Drug Administration (FDA) has granted clearance for marketing Zofran injection for PONV prevention.
• Clinical studies were conducted to assess Zofran's effectiveness.
• A specific dosage of 4 mg administered intravenously (IV) over 2 to 5 minutes was investigated.

Main Results:

• Zofran injection demonstrated good results in clinical studies.
• The medication was effective in reducing or preventing postoperative nausea and vomiting.
• Minimal adverse reactions were observed during the evaluation.

Conclusions:

• Zofran injection is a viable option for preventing and managing postoperative nausea and vomiting.
• The established dosage of 4 mg IV over 2 to 5 minutes appears safe and effective.
• Further clinical application of Zofran can improve patient outcomes after surgery.